Assessing Bio-Rad (BIO) Valuation After Mixed Share Price Performance And Recurring Revenue Shift

Bio-Rad Laboratories (BIO) has been drawing attention after a mixed stretch for the share price, with gains over the past year but declines over the past 3 months and year to date.

See our latest analysis for Bio-Rad Laboratories.

Recent trading has been choppy, with a 4.23% 7 day share price return following a weaker 30 day share price return of a 4.80% decline. A 12.23% decline over 90 days points to fading momentum despite a 9.02% 1 year total shareholder return.

If this mixed performance has you looking beyond a single name, it could be a good moment to broaden your search with our screener of 28 healthcare AI stocks.

With Bio-Rad trading at a discount to both analyst targets and some estimates of intrinsic value, the key question is whether you are looking at an undervalued life sciences player or a stock that already reflects its future growth.

Most Popular Narrative: 19.7% Undervalued

Bio-Rad Laboratories' most followed narrative pegs fair value at $348 per share versus the last close of $279.59, framing the current discount as valuation driven rather than just sentiment driven.

Resilience and stable growth in consumables and reagents, demonstrated by high single-digit growth, especially in the face of delayed academic and instrument funding, are shifting Bio-Rad's sales mix toward higher-margin, recurring revenues, supporting overall profitability and cash flow stability.

Read the complete narrative.

Curious how a steady consumables engine, softer earnings outlook, and a rich future earnings multiple can still support a higher fair value? The key hinges on how long margins stay compressed, how quickly recurring revenues reshape the mix, and what kind of premium the market might pay for those future cash flows. The full narrative joins those moving parts into one valuation story.

Result: Fair Value of $348 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you also need to weigh the risk that weak instrument demand and pressure in Clinical Diagnostics, particularly in China, could keep margins under strain for longer.

Find out about the key risks to this Bio-Rad Laboratories narrative.

Next Steps

With both risks and rewards highlighted, do you feel the balance tilts one way more than the other? Take a closer look now to weigh up the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

Before you move on, give yourself an edge by lining up a few new watchlist candidates using focused screens built to surface different types of opportunities.

• Target long term value by scanning a curated set of 45 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect their potential.
• Prioritise resilience by checking out our solid balance sheet and fundamentals stocks screener (41 results) to find companies with stronger financial footing and fewer balance sheet red flags.
• Stay ahead of the crowd with a screener containing 24 high quality undiscovered gems that highlights quality names still flying under most investors' radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com